Humacyte Inc
NASDAQ:HUMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Amer Sports Inc
NYSE:AS
|
FI |
|
EMV Capital PLC
LSE:EMVC
|
UK |
|
F
|
First Majestic Silver Corp
NYSE:AG
|
CA |
|
E
|
Eli Lilly and Co
XBER:LLY
|
US |
|
M
|
Metsa Board Oyj
OMXH:METSB
|
FI |
|
P
|
Porsche Automobil Holding SE
XBER:PAH3
|
DE |
|
IIFL Finance Ltd
NSE:IIFL
|
IN |
|
C
|
Cian Agro Industries & Infrastructure Ltd
BSE:519477
|
IN |
|
Luen Thai Holdings Ltd
HKEX:311
|
HK |
|
Focusrite PLC
LSE:TUNE
|
UK |
|
Indiabulls Real Estate Ltd
BSE:532832
|
IN |
Humacyte Inc
Total Current Liabilities
Humacyte Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Humacyte Inc
NASDAQ:HUMA
|
Total Current Liabilities
$18.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
Humacyte Inc
Glance View
Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.
See Also
What is Humacyte Inc's Total Current Liabilities?
Total Current Liabilities
18.4m
USD
Based on the financial report for Dec 31, 2025, Humacyte Inc's Total Current Liabilities amounts to 18.4m USD.
What is Humacyte Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
10%
Over the last year, the Total Current Liabilities growth was -8%. The average annual Total Current Liabilities growth rates for Humacyte Inc have been -2% over the past three years , 10% over the past five years .
